Cargando…

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer

Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirzaei, Hamid Reza, Sabet Rasekh, Parisa, Nasrollahi, Fatemeh, Sabet Rasekh, Parto, Akbari Tirabad, Zahra, Moein, Hamid Reza, Ghaffari Pour, Taban, Hajian, Parastoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800644/
https://www.ncbi.nlm.nih.gov/pubmed/24187626
http://dx.doi.org/10.1155/2013/404396
_version_ 1782288006724452352
author Mirzaei, Hamid Reza
Sabet Rasekh, Parisa
Nasrollahi, Fatemeh
Sabet Rasekh, Parto
Akbari Tirabad, Zahra
Moein, Hamid Reza
Ghaffari Pour, Taban
Hajian, Parastoo
author_facet Mirzaei, Hamid Reza
Sabet Rasekh, Parisa
Nasrollahi, Fatemeh
Sabet Rasekh, Parto
Akbari Tirabad, Zahra
Moein, Hamid Reza
Ghaffari Pour, Taban
Hajian, Parastoo
author_sort Mirzaei, Hamid Reza
collection PubMed
description Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer. Methods. All Patients first received 4 cycles of epirubicin (100 mg/m(2)) and cyclophosphamide (600 mg/m(2)) at 2-week interval then followed by docetaxel (100 mg/m(2)) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion. Results. Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure. Grade 3/4 neutropenia and febrile neutropenia were 13.8% and 5.1%. The most common grade 3/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%). Conclusions. Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation.
format Online
Article
Text
id pubmed-3800644
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38006442013-11-02 Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer Mirzaei, Hamid Reza Sabet Rasekh, Parisa Nasrollahi, Fatemeh Sabet Rasekh, Parto Akbari Tirabad, Zahra Moein, Hamid Reza Ghaffari Pour, Taban Hajian, Parastoo Int J Breast Cancer Clinical Study Background. Adding taxanes to anthracycline-based adjuvant chemotherapy has shown significant improvement particularly in node-positive patients, but optimal dose and schedule remain undetermined. Objectives. This study aimed to assess the feasibility of dose-dense epirubicin and cyclophosphamide followed by docetaxel in node-positive breast cancer. Methods. All Patients first received 4 cycles of epirubicin (100 mg/m(2)) and cyclophosphamide (600 mg/m(2)) at 2-week interval then followed by docetaxel (100 mg/m(2)) at 2-week interval for 4 cycles, with daily Pegfilgrastim (G-CSF) that was administered in all patients on days 3–10 after each cycle of epirubicin and cyclophosphamide infusion. Results. Fifty-eight patients with axillary lymph node-positive breast cancer were enrolled in the study, of whom 42 (72.4%) completed the regimen. There were two toxicity-related deaths, one patient due to grade 4 febrile neutropenia and the other due to congestive heart failure. Grade 3/4 neutropenia and febrile neutropenia were 13.8% and 5.1%. The most common grade 3/4 nonhematological complications were as follows: skin-nail disorders (48.3%), hand-foot syndrome (34.4%), paresthesia (38%), arthralgia (27.5%), and paresis (24.1%). Conclusions. Dose-dense epirubicin and cyclophosphamide followed by docetaxel with G-CSF support are not feasible, and it is not recommended for further investigation. Hindawi Publishing Corporation 2013 2013-09-25 /pmc/articles/PMC3800644/ /pubmed/24187626 http://dx.doi.org/10.1155/2013/404396 Text en Copyright © 2013 Hamid Reza Mirzaei et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Mirzaei, Hamid Reza
Sabet Rasekh, Parisa
Nasrollahi, Fatemeh
Sabet Rasekh, Parto
Akbari Tirabad, Zahra
Moein, Hamid Reza
Ghaffari Pour, Taban
Hajian, Parastoo
Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title_full Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title_fullStr Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title_full_unstemmed Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title_short Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
title_sort dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800644/
https://www.ncbi.nlm.nih.gov/pubmed/24187626
http://dx.doi.org/10.1155/2013/404396
work_keys_str_mv AT mirzaeihamidreza dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT sabetrasekhparisa dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT nasrollahifatemeh dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT sabetrasekhparto dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT akbaritirabadzahra dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT moeinhamidreza dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT ghaffaripourtaban dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer
AT hajianparastoo dosedenseepirubicinandcyclophosphamidefollowedbydocetaxelasadjuvantchemotherapyinnodepositivebreastcancer